Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VIRILON vs ORETON METHYL
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
Methyltestosterone is a synthetic androgen that binds to androgen receptors, activating transcription of androgen-responsive genes, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development.
Male hypogonadism (primary and hypogonadotropic),Delayed puberty in males,Off-label: Androgen replacement in transgender men, libido enhancement in women (limited use)
Hypogonadism,Delayed puberty,Metastatic breast cancer (palliative)
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
10-50 mg orally or buccally 1-3 times daily; or 25-100 mg IM every 2-4 weeks.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Terminal half-life approximately 2.7–3.8 hours; brief due to rapid hepatic metabolism.
Primarily hepatic via CYP3A4 and other CYP450 enzymes; metabolites are excreted in urine.
No dose adjustment required for renal impairment. Use with caution in patients with nephrotic syndrome due to potential fluid retention.
Not specifically required; caution in severe renal impairment due to potential fluid retention.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). For moderate impairment (Child-Pugh Class B), reduce dose to 100 mg every 2 weeks and monitor liver function.
WARNING: Use in men with breast cancer or known/suspected prostate cancer is contraindicated. Risk of accelerated growth of prostate cancer and exacerbation of breast cancer.
Testosterone esters (e.g., testosterone cypionate, testosterone enanthate) are contraindicated in pregnancy. Androgens can cause virilization of the female fetus, including clitoromegaly, labial fusion, and urogenital sinus abnormalities, especially during the first trimester when genital differentiation occurs. Risk is dose-dependent and increases with higher maternal androgen levels. No adequate human studies; animal studies show teratogenic effects at high doses.
Androgenic progestins like methyltestosterone (ORETON METHYL) are associated with virilization of female fetuses, including clitoromegaly and labial fusion, particularly during the first trimester. Use in pregnancy is contraindicated.
VIRILON (methyltestosterone) is an androgen used for testosterone replacement therapy. Monitor liver function tests due to risk of hepatotoxicity. Avoid in patients with prostate or breast cancer. May cause priapism, gynecomastia, and edema. Use with caution in elderly due to increased risk of prostatic hyperplasia.
Oreton Methyl (methyltestosterone) is a 17-alpha-alkylated androgen; monitor liver function tests due to hepatotoxicity risk; avoid use in women of childbearing potential; can cause virilization in women; use with caution in older men due to prostatic hyperplasia risk; may enhance warfarin effect; can cause erythrocytosis; check hemoglobin/hematocrit periodically; therapeutic range not well-defined; administer orally with food to reduce GI upset.
No interactions on record
No interactions on record
VIRILON and ORETON METHYL are distinct pharmacological agents. VIRILON belongs to the Androgen class and is primarily used for Male hypogonadism (primary and hypogonadotropic)Delayed puberty in malesOff-label: Androgen replacement in transgender men, libido enhancement in women (limited use). ORETON METHYL belongs to the Androgen class and is primarily used for HypogonadismDelayed pubertyMetastatic breast cancer (palliative). Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. VIRILON carries a safety status of Category C, whereas ORETON METHYL safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism, resulting in low oral bioavailability.
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Primarily renal as conjugated metabolites; ~90% urinary, ~6% fecal within 4 days.
Approximately 95% bound to plasma proteins, primarily sex hormone-binding globulin (SHBG) and albumin.
~97–99% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Apparent volume of distribution is approximately 0.5–1.0 L/kg, indicating distribution into total body water with some tissue binding.
0.4–0.6 L/kg; moderate distribution, mainly to muscle and prostate.
Oral bioavailability is approximately 40–60% due to extensive first-pass metabolism in the liver. Sublingual administration may achieve higher systemic exposure.
Oral: low ~6% due to first-pass metabolism. IM: 100%. Buccal: ~20–25%.
Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or use with caution.
Not recommended for use in pediatric patients. Safety and efficacy have not been established; may cause premature epiphyseal closure and virilization.
Not recommended for use in children; safety and efficacy not established.
Use with caution in elderly patients due to increased risk of prostatic hypertrophy and prostatic carcinoma. Monitor prostate-specific antigen (PSA) regularly. Consider lower starting dose of 100 mg every 2 weeks.
Use with caution; monitor for prostate enlargement, fluid retention, and cardiovascular effects. Start at lower end of dosing range.
Prolonged use of high doses of methyltestosterone has been associated with serious hepatic adverse effects, including peliosis hepatis, hepatic neoplasms, and hepatocellular carcinoma.
Monitor liver function; risk of hepatic toxicity including cholestatic hepatitis and jaundice; may cause fluid retention, especially in patients with cardiac, renal, or hepatic disease; may cause hypercalcemia in immobile patients or those with metastatic breast cancer; may suppress spermatogenesis; may cause gynecomastia; may accelerate bone maturation in children; may cause priapism; may affect serum lipids; may cause polycythemia; use with caution in patients with diabetes (may alter insulin sensitivity).
Known or suspected prostate cancer; male breast cancer; hypersensitivity to methyltestosterone; pregnancy; breastfeeding; severe hepatic impairment.
Take with food to reduce GI upset. Avoid grapefruit juice as it may increase methyltestosterone levels. Alcohol consumption may exacerbate hepatotoxicity.
No specific food interactions are documented; however, taking with a meal may reduce gastrointestinal upset. Avoid grapefruit juice as it may alter drug metabolism via CYP3A4.
Testosterone is excreted into breast milk in small amounts; M/P ratio is not established. Use in nursing mothers is not recommended due to potential adverse effects on the infant, including virilization and disruption of hormonal balance. Alternative therapies should be considered if breastfeeding is desired.
Methyltestosterone is excreted into breast milk. The M/P ratio is not established. Potential for adverse effects in the nursing infant, including virilization, and suppression of lactation. Breastfeeding is not recommended.
Not applicable; use during pregnancy is contraindicated. No dose adjustment studies exist. If inadvertent use occurs, discontinue immediately and monitor for fetal effects. Pharmacokinetic changes during pregnancy (e.g., increased volume of distribution, altered metabolism) would likely require dose adjustments if use were considered, but due to teratogenicity, no safe dosing regimen can be recommended.
No therapeutic indication for use in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) are not relevant due to contraindication.
Take exactly as prescribed; do not increase dose or frequency.,Report symptoms of priapism (prolonged erection), jaundice, or edema immediately.,Regular blood tests (liver function, PSA, lipid profile) are required.,Avoid alcohol as it may increase risk of liver damage.,Women of childbearing age should use effective contraception due to potential virilization of fetus.,Do not use if you have a history of prostate or breast cancer.
Take this medication exactly as prescribed and do not change dose without consulting your doctor.,Report any signs of liver problems (yellowing of skin/eyes, dark urine, abdominal pain) or unusual bleeding/bruising immediately.,Men should be aware of possible changes in urinary habits or breast swelling/tenderness.,Women should use effective contraception and avoid pregnancy; report voice deepening, excessive hair growth, or menstrual irregularities.,Do not use this medication if you have prostate cancer or breast cancer in men.,Regular blood tests (liver function, complete blood count, prostate-specific antigen) are necessary while on this medication.,This medication may interact with blood thinners (warfarin), so frequent INR monitoring is needed.,Avoid alcohol as it may worsen liver effects.